• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自然杀伤细胞在胶质母细胞瘤治疗中的研究进展

Research Progress of NK Cells in Glioblastoma Treatment.

作者信息

Wu Hao, Liu Qi, Wang Fenglu, Gao Wenwen, Zhou Feng, Zhao Haikang

机构信息

Department of Neurosurgery, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, People's Republic of China.

Department of Neurosurgery, The First Hospital of Yulin, Yulin, People's Republic of China.

出版信息

Onco Targets Ther. 2025 Jan 18;18:87-106. doi: 10.2147/OTT.S486411. eCollection 2025.

DOI:10.2147/OTT.S486411
PMID:39845286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11752833/
Abstract

NK cells are a type of antitumor immune cell with promising clinical application, following T cells. The activity of NK cells is primarily regulated by their surface receptors and immune microenvironment. In gliomas, the tumor microenvironment exerts a strong immunosuppressive effect, which significantly reduces the clinical efficacy of NK cell immunotherapy. Therefore, this review aims to discuss the latest research on the role of NK cells in glioma immunotherapy, focusing on aspects such as NK cell development, function, and localization. It summarizes information on the compounds, monoclonal antibodies, and cytokine therapies targeting NK cells while emphasizing the current status and trends of gene-modified NK cells in glioma treatment. Additionally, it explores the molecular mechanisms underlying immune escape in glioma cells, providing a theoretical foundation and new perspectives for NK cell-based immunotherapy in gliomas.

摘要

自然杀伤细胞（NK细胞）是继T细胞之后具有广阔临床应用前景的一类抗肿瘤免疫细胞。NK细胞的活性主要受其表面受体和免疫微环境的调节。在胶质瘤中，肿瘤微环境具有强大的免疫抑制作用，这显著降低了NK细胞免疫治疗的临床疗效。因此，本综述旨在探讨NK细胞在胶质瘤免疫治疗中作用的最新研究，重点关注NK细胞的发育、功能和定位等方面。它总结了针对NK细胞的化合物、单克隆抗体和细胞因子疗法的相关信息，同时强调了基因修饰NK细胞在胶质瘤治疗中的现状和趋势。此外，还探讨了胶质瘤细胞免疫逃逸的分子机制，为基于NK细胞的胶质瘤免疫治疗提供理论基础和新的视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/08180fbeba59/OTT-18-87-g0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/2ee341ca48aa/OTT-18-87-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/4148a58460ce/OTT-18-87-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/2a44c4ce1df2/OTT-18-87-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/f4a32592fb3e/OTT-18-87-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/f3e0edcaa3c3/OTT-18-87-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/0c8c998f8447/OTT-18-87-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/6a92199f96e2/OTT-18-87-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/7fc47d80f7ed/OTT-18-87-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/c7a69dd5becb/OTT-18-87-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/6096d355d665/OTT-18-87-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/cb6f771a794d/OTT-18-87-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/903749698b07/OTT-18-87-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/08180fbeba59/OTT-18-87-g0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/2ee341ca48aa/OTT-18-87-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/4148a58460ce/OTT-18-87-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/2a44c4ce1df2/OTT-18-87-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/f4a32592fb3e/OTT-18-87-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/f3e0edcaa3c3/OTT-18-87-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/0c8c998f8447/OTT-18-87-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/6a92199f96e2/OTT-18-87-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/7fc47d80f7ed/OTT-18-87-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/c7a69dd5becb/OTT-18-87-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/6096d355d665/OTT-18-87-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/cb6f771a794d/OTT-18-87-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/903749698b07/OTT-18-87-g0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/11752833/08180fbeba59/OTT-18-87-g0013.jpg

相似文献

1
Research Progress of NK Cells in Glioblastoma Treatment.自然杀伤细胞在胶质母细胞瘤治疗中的研究进展
Onco Targets Ther. 2025 Jan 18;18:87-106. doi: 10.2147/OTT.S486411. eCollection 2025.
2
NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas.基于自然杀伤细胞的免疫疗法及在胶质瘤中的治疗前景
Front Oncol. 2021 Oct 26;11:751183. doi: 10.3389/fonc.2021.751183. eCollection 2021.
3
NK Cell-Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities.基于自然杀伤细胞的癌症免疫疗法：当前进展、挑战和新机遇。
J Biochem Mol Toxicol. 2024 Nov;38(11):e70044. doi: 10.1002/jbt.70044.
4
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.逃避自然杀伤 (NK) 细胞的潜在机制作为改善基于 NK 细胞的免疫疗法的依据。
Front Immunol. 2022 Aug 12;13:910595. doi: 10.3389/fimmu.2022.910595. eCollection 2022.
5
Immune suppression in gliomas.胶质瘤的免疫抑制。
J Neurooncol. 2021 Jan;151(1):3-12. doi: 10.1007/s11060-020-03483-y. Epub 2020 Jun 15.
6
Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.脑胶质瘤肿瘤微环境的特征及其与新兴免疫治疗模式的相互作用。
Int J Mol Sci. 2023 Aug 25;24(17):13215. doi: 10.3390/ijms241713215.
7
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?在肿瘤微环境中释放自然杀伤细胞——下一代免疫疗法？
Front Immunol. 2020 Feb 21;11:275. doi: 10.3389/fimmu.2020.00275. eCollection 2020.
8
NK/DC crosstalk-modulating antitumor activity via Sema3E/PlexinD1 axis for enhanced cancer immunotherapy.NK细胞与树突状细胞的相互作用通过Sema3E/神经纤毛蛋白D1轴调节抗肿瘤活性以增强癌症免疫治疗。
Immunol Res. 2024 Dec;72(6):1217-1228. doi: 10.1007/s12026-024-09536-y. Epub 2024 Sep 5.
9
In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.地西他滨作为一种自然杀伤细胞介导的免疫疗法治疗异柠檬酸脱氢酶突变型神经胶质瘤的体内疗效。
Neurosurg Focus. 2022 Feb;52(2):E3. doi: 10.3171/2021.11.FOCUS21489.
10
Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.以自然杀伤细胞为基础的癌症免疫疗法治疗癌症：通往充满希望之地的艰难之旅。
Biomed Pharmacother. 2023 Sep;165:115004. doi: 10.1016/j.biopha.2023.115004. Epub 2023 Jun 21.

本文引用的文献

1
Five decades of natural killer cell discovery.自然杀伤细胞发现的五十年。
J Exp Med. 2024 Aug 5;221(8). doi: 10.1084/jem.20231222. Epub 2024 Jun 6.
2
CAR-NK cells in combination therapy against cancer: A potential paradigm.嵌合抗原受体自然杀伤细胞在癌症联合治疗中的应用：一种潜在模式。
Heliyon. 2024 Feb 29;10(5):e27196. doi: 10.1016/j.heliyon.2024.e27196. eCollection 2024 Mar 15.
3
Surface Engineering of Natural Killer Cells with CD44-targeting Ligands for Augmented Cancer Immunotherapy.利用靶向 CD44 的配体对自然杀伤细胞进行表面工程改造以增强癌症免疫治疗。
Small. 2024 Jun;20(24):e2306738. doi: 10.1002/smll.202306738. Epub 2023 Dec 31.
4
Resting natural killer cell homeostasis relies on tryptophan/NAD metabolism and HIF-1α.静息自然杀伤细胞的内稳态依赖于色氨酸/NAD 代谢和 HIF-1α。
EMBO Rep. 2023 Jun 5;24(6):e56156. doi: 10.15252/embr.202256156. Epub 2023 Mar 29.
5
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.临床开发中的自然杀伤细胞作为非工程化、工程化和联合疗法。
J Hematol Oncol. 2022 Nov 8;15(1):164. doi: 10.1186/s13045-022-01382-5.
6
Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities.脂质介导的细胞表面体外工程增强细胞功能。
Biomater Adv. 2022 Sep;140:213059. doi: 10.1016/j.bioadv.2022.213059. Epub 2022 Aug 3.
7
Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation.EPH 受体 A5 在肺腺癌中的表达与淋巴结转移和 EGFR 突变相关。
APMIS. 2022 Jun;130(6):338-345. doi: 10.1111/apm.13222. Epub 2022 Apr 4.
8
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.利用自然杀伤细胞进行癌症免疫治疗：派遣第一响应者。
Nat Rev Drug Discov. 2022 Aug;21(8):559-577. doi: 10.1038/s41573-022-00413-7. Epub 2022 Mar 21.
9
elimination of EL4 cancer cells from spermatogonia stem cells by miRNA-143- and 206-loaded folic acid-conjugated PLGA nanoparticles.通过负载miRNA - 143和206的叶酸共轭聚乳酸 - 羟基乙酸共聚物纳米颗粒从精原干细胞中消除EL4癌细胞。
Nanomedicine (Lond). 2022 Apr;17(8):531-545. doi: 10.2217/nnm-2021-0210. Epub 2022 Mar 10.
10
Expression of IL-37 Correlates With Immune Cell Infiltrate and Fibrosis in Pediatric Autoimmune Liver Diseases.IL-37 的表达与小儿自身免疫性肝病中的免疫细胞浸润和纤维化相关。
J Pediatr Gastroenterol Nutr. 2022 Jun 1;74(6):742-749. doi: 10.1097/MPG.0000000000003443. Epub 2022 Mar 7.